A hereditaer és sporadikus colorectalis daganatok genetikája és a genetikai ismeretek jelentosége a mindennapi gyakorlatban

Sporadikus és IBD-asszociált colorectalis tumorok, illetve a genetikai vizsgálatok jelentosége a diagnózisban, prognózisban és a kemoterapiara adott valasz megitelesében

Translated title of the contribution: Current concepts on the genetics of hereditary and sporadic colorectal cancer and the role of genetics in the patient management

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

There has been a major improvement in our understanding in the area of the genetics of CRC in the last decade. Reason for this is partly that CRC has a strong hereditary trait and premalignant lesions are frequent and easily accessible. In the 1990s the mutations responsible for the adenoma-carcinoma sequence were discovered on after the other. In the second part of the review the authors discuss the genetic background of sporadic and IBD associated colorectal cancers as well as the role of genetics in the diagnosis, prognosis and prediction of therapy. Chromosomal instability (85%) and microsatellite instability with or without change in DNA methylation (15%) are the main mechanisms involved in the pathogenesis of sporadic colorectal cancers. It became evident that no ultimate mutations exist. Most of neoplasms are genetically heterogeneous, independent pathways and simultaneous tumorigenesis may exist within the same organ, also in the colon. Gene expression profile, clinical phenotype and prognosis may also vary according to the location. Similar genetic mutations may be found in IBD associated colorectal cancers, however, the typical sequence and importance of mutations is different. In future, fecal DNA testing may be an impotant screening tool for colorectal cancer; however, its routine use is still limited by its low sensitivity. Similarly, genetic investigation may play an increasing role in the prediction of prognosis, therapy and complication of chemotherapy. A more distant goal may be the individualization of the therapy.

Original languageHungarian
Pages (from-to)449-455
Number of pages7
JournalOrvosi Hetilap
Volume147
Issue number10
Publication statusPublished - Mar 12 2006

Fingerprint

Genetic Phenomena
Colorectal Neoplasms
Mutation
Chromosomal Instability
Microsatellite Instability
DNA Methylation
Transcriptome
Adenoma
Colon
Carcinogenesis
Therapeutics
Carcinoma
Phenotype
Drug Therapy
DNA
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{f90185fa5d004bc29f751b67e4bda926,
title = "A hereditaer {\'e}s sporadikus colorectalis daganatok genetik{\'a}ja {\'e}s a genetikai ismeretek jelentos{\'e}ge a mindennapi gyakorlatban: Sporadikus {\'e}s IBD-asszoci{\'a}lt colorectalis tumorok, illetve a genetikai vizsg{\'a}latok jelentos{\'e}ge a diagn{\'o}zisban, progn{\'o}zisban {\'e}s a kemoterapiara adott valasz megiteles{\'e}ben",
abstract = "There has been a major improvement in our understanding in the area of the genetics of CRC in the last decade. Reason for this is partly that CRC has a strong hereditary trait and premalignant lesions are frequent and easily accessible. In the 1990s the mutations responsible for the adenoma-carcinoma sequence were discovered on after the other. In the second part of the review the authors discuss the genetic background of sporadic and IBD associated colorectal cancers as well as the role of genetics in the diagnosis, prognosis and prediction of therapy. Chromosomal instability (85{\%}) and microsatellite instability with or without change in DNA methylation (15{\%}) are the main mechanisms involved in the pathogenesis of sporadic colorectal cancers. It became evident that no ultimate mutations exist. Most of neoplasms are genetically heterogeneous, independent pathways and simultaneous tumorigenesis may exist within the same organ, also in the colon. Gene expression profile, clinical phenotype and prognosis may also vary according to the location. Similar genetic mutations may be found in IBD associated colorectal cancers, however, the typical sequence and importance of mutations is different. In future, fecal DNA testing may be an impotant screening tool for colorectal cancer; however, its routine use is still limited by its low sensitivity. Similarly, genetic investigation may play an increasing role in the prediction of prognosis, therapy and complication of chemotherapy. A more distant goal may be the individualization of the therapy.",
keywords = "Colorectal cancer, CRC, FAP, Genetics, HNPCC, IBD associated CRC, Peutz-Jeghers syndrome, Pharmacogenetics, Prognosis",
author = "P. Lakatos and L. Lakatos",
year = "2006",
month = "3",
day = "12",
language = "Hungarian",
volume = "147",
pages = "449--455",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "10",

}

TY - JOUR

T1 - A hereditaer és sporadikus colorectalis daganatok genetikája és a genetikai ismeretek jelentosége a mindennapi gyakorlatban

T2 - Sporadikus és IBD-asszociált colorectalis tumorok, illetve a genetikai vizsgálatok jelentosége a diagnózisban, prognózisban és a kemoterapiara adott valasz megitelesében

AU - Lakatos, P.

AU - Lakatos, L.

PY - 2006/3/12

Y1 - 2006/3/12

N2 - There has been a major improvement in our understanding in the area of the genetics of CRC in the last decade. Reason for this is partly that CRC has a strong hereditary trait and premalignant lesions are frequent and easily accessible. In the 1990s the mutations responsible for the adenoma-carcinoma sequence were discovered on after the other. In the second part of the review the authors discuss the genetic background of sporadic and IBD associated colorectal cancers as well as the role of genetics in the diagnosis, prognosis and prediction of therapy. Chromosomal instability (85%) and microsatellite instability with or without change in DNA methylation (15%) are the main mechanisms involved in the pathogenesis of sporadic colorectal cancers. It became evident that no ultimate mutations exist. Most of neoplasms are genetically heterogeneous, independent pathways and simultaneous tumorigenesis may exist within the same organ, also in the colon. Gene expression profile, clinical phenotype and prognosis may also vary according to the location. Similar genetic mutations may be found in IBD associated colorectal cancers, however, the typical sequence and importance of mutations is different. In future, fecal DNA testing may be an impotant screening tool for colorectal cancer; however, its routine use is still limited by its low sensitivity. Similarly, genetic investigation may play an increasing role in the prediction of prognosis, therapy and complication of chemotherapy. A more distant goal may be the individualization of the therapy.

AB - There has been a major improvement in our understanding in the area of the genetics of CRC in the last decade. Reason for this is partly that CRC has a strong hereditary trait and premalignant lesions are frequent and easily accessible. In the 1990s the mutations responsible for the adenoma-carcinoma sequence were discovered on after the other. In the second part of the review the authors discuss the genetic background of sporadic and IBD associated colorectal cancers as well as the role of genetics in the diagnosis, prognosis and prediction of therapy. Chromosomal instability (85%) and microsatellite instability with or without change in DNA methylation (15%) are the main mechanisms involved in the pathogenesis of sporadic colorectal cancers. It became evident that no ultimate mutations exist. Most of neoplasms are genetically heterogeneous, independent pathways and simultaneous tumorigenesis may exist within the same organ, also in the colon. Gene expression profile, clinical phenotype and prognosis may also vary according to the location. Similar genetic mutations may be found in IBD associated colorectal cancers, however, the typical sequence and importance of mutations is different. In future, fecal DNA testing may be an impotant screening tool for colorectal cancer; however, its routine use is still limited by its low sensitivity. Similarly, genetic investigation may play an increasing role in the prediction of prognosis, therapy and complication of chemotherapy. A more distant goal may be the individualization of the therapy.

KW - Colorectal cancer

KW - CRC

KW - FAP

KW - Genetics

KW - HNPCC

KW - IBD associated CRC

KW - Peutz-Jeghers syndrome

KW - Pharmacogenetics

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=33750537921&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750537921&partnerID=8YFLogxK

M3 - Article

VL - 147

SP - 449

EP - 455

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 10

ER -